Asset profile
Letrozole
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Letrozole: this drug | Approved | Small molecule | Aromatase | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Exemestane | Approved | Small molecule | Aromatase | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Eribulin Mesylate | Approved | Small molecule | Tubulin / microtubules | ||
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Gedatolisib | Approved | Small molecule | PI3K (class I isoforms) and mTORC1/mTORC2 | ||
| Gemcitabine | Approved | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) |
…and 47 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(101 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (14)
November 2026 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT04906395 · CT.gov ↗
What to watch
December 2026 (13)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05307705 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06974929 · CT.gov ↗
What to watch
Phase 2Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial CancerRecruiting
Est. primary completion 2026-12 · NCT05997017 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05780567 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04393285 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-22 · NCT04886531 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT07492394 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05286437 · CT.gov ↗
What to watch
Phase 4Ectopic PregnancyRecruiting
Est. primary completion 2026-12-31 · NCT06354439 · CT.gov ↗
What to watch
Early phase / not applicableEndometriotic Cyst of OvaryRecruiting
Est. primary completion 2026-12-31 · NCT05487092 · CT.gov ↗
What to watch
2027 (33)
January 2027 (2)
February 2027 (4)
Early phase / not applicableInfertility Female, Frozen Embryo Transfer (FET)Recruiting
Est. primary completion 2027-02 · NCT07425990 · CT.gov ↗
What to watch
Phase 3Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma …Active not recruiting
Est. primary completion 2027-02-01 · NCT04095364 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT05262400 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-26 · NCT01872260 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07305246 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03-01 · NCT06179303 · CT.gov ↗
What to watch
Early phase / not applicableLetrozoleNot yet recruiting
Est. primary completion 2027-03-01 · NCT07753655 · CT.gov ↗
What to watch
Phase 2Endometrial Neoplasm Malignant Stage IRecruiting
Est. primary completion 2027-03-10 · NCT05247268 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2Low-Grade Serous Ovarian CancerRecruiting
Est. primary completion 2027-04 · NCT06394804 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-15 · NCT05464810 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-15 · NCT04614194 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
May 2027 (1)
Early phase / not applicableAdenomyosis of Uterus, Frozen Embryo Transfer (FET)Not yet recruiting
Est. primary completion 2027-05 · NCT07065539 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Ectopic PregnancyNot yet recruiting
Est. primary completion 2027-06 · NCT07624903 · CT.gov ↗
What to watch
July 2027 (5)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07394946 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT04469764 · CT.gov ↗
What to watch
Phase 3Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Peritoneal Neoplasms, High-grade Serous Ovarian Carcinoma (HGSOC) …Recruiting
Est. primary completion 2027-07-01 · NCT04111978 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07029399 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07054190 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08 · NCT05181033 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (2)
November 2027 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2027-11-04 · NCT06979596 · CT.gov ↗
What to watch
December 2027 (6)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT06555068 · CT.gov ↗
What to watch
Early phase / not applicableSilent MiscarriageNot yet recruiting
Est. primary completion 2027-12-05 · NCT06733727 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07285382 · CT.gov ↗
What to watch
Phase 2/3Endometrial Cancer, FertilityRecruiting
Est. primary completion 2027-12-31 · NCT07319429 · CT.gov ↗
What to watch
2028 (20)
January 2028 (3)
Phase 2Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell TumorRecruiting
Est. primary completion 2028-01 · NCT05872204 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-30 · NCT07691333 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-31 · NCT05867251 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07676331 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07795424 · CT.gov ↗
What to watch
Phase 3InfertilityRecruiting
Est. primary completion 2028-03-31 · NCT03011684 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-04-02 · NCT04568616 · CT.gov ↗
What to watch
May 2028 (2)
June 2028 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-06 · NCT02918084 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Uterine LeiomyosarcomaRecruiting
Est. primary completion 2028-07-30 · NCT05649956 · CT.gov ↗
What to watch
August 2028 (4)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08 · NCT06998407 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-08-01 · NCT03675893 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-15 · NCT05467891 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma …Active not recruiting
Est. primary completion 2028-08-31 · NCT03008408 · CT.gov ↗
What to watch
September 2028 (2)
2029 (16)
January 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2029-01-02 · NCT06760637 · CT.gov ↗
What to watch
February 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07340658 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-03-31 · NCT06757634 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT07492641 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05 · NCT07174336 · CT.gov ↗
What to watch
June 2029 (2)
July 2029 (3)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07-01 · NCT07061717 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-07-13 · NCT04606446 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-07-31 · NCT07391774 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch
September 2029 (2)
December 2029 (3)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12 · NCT06120283 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-18 · NCT06380751 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2029-12-31 · NCT05226871 · CT.gov ↗
What to watch
2030 (9)
March 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerEnrolling by invitation
Est. primary completion 2030-03 · NCT05645536 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-06-28 · NCT05161195 · CT.gov ↗
What to watch
July 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗
What to watch
September 2030 (2)
October 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-10 · NCT04584853 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-04-08 · NCT04852887 · CT.gov ↗
What to watch
May 2031 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-05-09 · NCT07288359 · CT.gov ↗
What to watch
2032 (4)
January 2032 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2032-01-31 · NCT06790693 · CT.gov ↗
What to watch
March 2032 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-03-23 · NCT07679269 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2032-05-02 · NCT06223698 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2032-06-08 · NCT07604571 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.